News | November 05, 2006

PAD Diagnosis is Catastrophic for Dialysis Patients

A new study published in the Oct. 30 edition of “Circulation” calls the onset of peripheral arterial disease (PAD) among dialysis patients “catastrophic.” Millions of people around the world who suffer from end-stage kidney disease endure numerous complicated lifestyle changes once they begin dialysis, the diagnosis of PAD not only adds to their deteriorated quality of life but, increases their overall risk of dying by 36 percent,” the study’s authors said.

Led by Dr. Sanjay Rajagopalan, a cardiologist at the Ohio State University Medical Center, the study examined the health records of nearly 30,000 dialysis patients enrolled from 1996 to 2004 in the Dialysis Outcomes and Practice Patterns Study (DOPPS) in North America, Europe, Japan and Australia.

Peripheral arterial disease occurs when cholesterol or plaque builds up in the arteries outside the heart – typically in the legs or pelvis – limiting normal blood flow and increasing the risk of heart attack or stroke. It’s estimated that about three percent of the American population under the ago of 60 has some degree of PAD but may be unaware of it. More than 20 percent of individuals above age 70 suffer from some form of the disease.

“What the data is telling us is that peripheral artery disease is very, very serious – just as serious as having had a heart attack or a stroke,” said Dr. Rajagopalan. “It is not a pretty picture.”

The study found that dialysis patients with PAD, when compared to those patients without the disease, were generally about twice as likely to be suffering from a number of other conditions that increased their risk of death, including coronary artery disease, congestive heart failure, cerebrovascular disease or diabetes.

Related Content

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init